Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $34.4100 (-0.29%) ($34.4100 - $34.4100) on Sun. May. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.47% (three month average) | RSI | 22 | Latest Price | $34.4100(-0.29%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -3.1% a day on average for past five trading days. | Weekly Trend | TGTX declines -9.1% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting TGTX price | TGTX will decline at least -1.735% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.735% (StdDev 3.47%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $23.25(-32.43%) | Resistance Level | $40.5 | 5 Day Moving Average | $36.23(-5.02%) | 10 Day Moving Average | $38.5(-10.62%) | 20 Day Moving Average | $40.5(-15.04%) | To recent high | -31.7% | To recent low | 0% | Market Cap | $N/A | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |